
|Videos|May 24, 2017
The Development of Galectin-1 for Head and Neck Cancer
Author(s)Dhanya K. Nambier, PhD
Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.
Advertisement
Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.
According to Nambiar, Galectin-1 is a target that should continue to be developed in combinatorial approaches so that it can eventually be investigated in clinical trials.
Additionally, it might be important to study Galectin-1 in different cancer types to determine if there is a similar correlation to what is demonstrated in head and neck cancer, states Nambiar.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































